GSK Plc (GSK)
50.75
-0.46
(-0.90%)
USD |
NYSE |
Oct 23, 16:00
50.74
0.00 (0.00%)
Pre-Market: 20:00
GSK Enterprise Value : 122.11B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 122.11B |
| October 22, 2026 | 123.05B |
| October 21, 2026 | 120.64B |
| October 20, 2026 | 121.87B |
| October 19, 2026 | 119.51B |
| October 16, 2026 | 119.61B |
| October 15, 2026 | 118.62B |
| October 14, 2026 | 116.29B |
| October 13, 2026 | 113.05B |
| October 12, 2026 | 114.37B |
| October 09, 2026 | 113.52B |
| October 08, 2026 | 113.60B |
| October 07, 2026 | 114.57B |
| October 06, 2026 | 113.72B |
| October 05, 2026 | 113.62B |
| October 02, 2026 | 114.59B |
| October 01, 2026 | 114.89B |
| September 30, 2026 | 116.90B |
| September 29, 2026 | 119.28B |
| September 28, 2026 | 119.99B |
| September 25, 2026 | 119.06B |
| September 24, 2026 | 119.89B |
| September 23, 2026 | 120.01B |
| September 22, 2026 | 122.05B |
| September 21, 2026 | 122.78B |
| Date | Value |
|---|---|
| September 18, 2026 | 121.04B |
| September 17, 2026 | 122.74B |
| September 16, 2026 | 121.18B |
| September 15, 2026 | 120.62B |
| September 14, 2026 | 120.70B |
| September 11, 2026 | 116.82B |
| September 10, 2026 | 116.79B |
| September 09, 2026 | 117.83B |
| September 08, 2026 | 117.64B |
| September 04, 2026 | 120.38B |
| September 03, 2026 | 122.36B |
| September 02, 2026 | 121.49B |
| September 01, 2026 | 121.93B |
| August 31, 2026 | 121.10B |
| August 28, 2026 | 122.26B |
| August 27, 2026 | 121.14B |
| August 26, 2026 | 123.49B |
| August 25, 2026 | 124.78B |
| August 24, 2026 | 124.20B |
| August 21, 2026 | 125.47B |
| August 20, 2026 | 124.56B |
| August 19, 2026 | 126.42B |
| August 18, 2026 | 122.92B |
| August 17, 2026 | 121.16B |
| August 14, 2026 | 119.63B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 558.20B |
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
| Merck & Co., Inc. | 405.39B |
| Novo Nordisk A/S | 145.21B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 742.26M |
| Revenue (Quarterly) | 11.29B |
| Total Expenses (Quarterly) | 10.70B |
| EPS Diluted (Quarterly) | 0.2875 |
| Gross Profit Margin (Quarterly) | 75.05% |
| Profit Margin (Quarterly) | 6.58% |
| Earnings Yield | 6.25% |
| Operating Earnings Yield | 10.76% |
| Normalized Earnings Yield | 9.087 |